View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
March 23, 2011

Freshmedx Reports Positive Results from Lung Cancer Test Study

Freshmedx has reported positive results from a clinical trial of computerised bioconductance test (CB test), a lung cancer test which is used to distinguish between benign and malignant indeterminate masses. In the trial, the CB test demonstrated 90% sensitivity and 92% specificity in

By cms admin

Freshmedx has reported positive results from a clinical trial of computerised bioconductance test (CB test), a lung cancer test which is used to distinguish between benign and malignant indeterminate masses.

In the trial, the CB test demonstrated 90% sensitivity and 92% specificity in distinguishing between benign and malignant masses in undiagnosed individuals with lung cancer symptoms.

The CB test is non-invasive, involves no ionising radiation and is based on characterisation of a radiologically indeterminate lung mass.

Freshmedx clinical affairs vice-president Karleen Callahan said the technology had the potential to reduce the stressful waiting period for those who have indeterminate masses and often undergo additional CT evaluation prior to receiving biopsy.

“It helps inform the physician whether an immediate biopsy is warranted or if longer term, radiological follow-up is appropriate,” Callahan added.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management